Table 1 Demographic and clinical symptom assessment of depressed patients at baseline
| Â | All Enrolled Patients | Per-Protocol Set (PPS) | |||
|---|---|---|---|---|---|
Agomelatine Group (n = 90) | SSRIs Group (n = 90) | Agomelatine Group (n = 77) | SSRIs Group (n = 77) | ||
Demographic Data | |||||
Gender (n, %) | Males (54) | 23 (42.6) | 31 (57.4) | 19 (42.2) | 26 (57.8) |
Females (126) | 67 (53.2) | 59 (46.8) | 58 (53.2) | 51 (46.8) | |
First episode or relapse (n, %) | First episode (102) | 49 (48) | 53 (52) | 43 (49.4) | 44 (50.6) |
Relapse (78) | 41 (52.6) | 37 (47.4) | 34 (50.8) | 33 (49.3) | |
Age (years, x ± s) | 42.8 ± 11.5 | 44.6 ± 12.6 | 42.5 ± 11.5 | 44.4 ± 14.9 | |
BMI (Kg/m2, x ± s) | 21.8 ± 2.8 | 21.5 ± 2.8 | 21.5 ± 3.0 | 21.9 ± 2.9 | |
Clinical Symptom Assessment | |||||
HAMD-17 (score, x ± s) | 22.7 ± 6.4 | 22.3 ± 4.6 | 22.0 ± 4.3 | 23.1 ± 6.8 | |
HAMA (score, x ± s) | 21.0 ± 8.4 | 20.0 ± 8.2 | 21.88 ± 8.8 | 20.1 ± 7.8 | |
SHAPS (score, x ± s) | 45.4 ± 5.8 | 45.6 ± 5.7 | 45.8 ± 5.6 | 45.5 ± 5.9 | |
MFI-20 (score, x ± s) | 79.0 ± 12.1 | 79.2 ± 11.4 | 79.2 ± 12.5 | 79.2 ± 11.8 | |
MEQ (score, x ± s) | 51.8 ± 9.6 | 52.9 ± 8.8 | 51.6 ± 9.7 | 52.8 ± 9.3 | |
PSQI (score, x ± s) | 14.4 ± 3.4 | 14.7 ± 3.3 | 14.6 ± 3.3 | 14.3 ± 3.5 | |